Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 383

1.

Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.

Maixnerova D, Ling C, Hall S, Reily C, Brown R, Neprasova M, Suchanek M, Honsova E, Zima T, Novak J, Tesar V.

PLoS One. 2019 Jul 12;14(7):e0219947. doi: 10.1371/journal.pone.0219947. eCollection 2019.

PMID:
31299057
Free Article
2.

Nephrology in the Eastern and Central European region: challenges and opportunities.

Spasovski G, Rroji M, Vazelov E, Basic Jukic N, Tesar V, Mugosa Ratkovic M, Covic A, Naumovic R, Resic H, Turan Kazancioglu R.

Kidney Int. 2019 Apr 12. pii: S0085-2538(19)30342-4. doi: 10.1016/j.kint.2019.02.040. [Epub ahead of print] No abstract available.

PMID:
31200943
3.

Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal.

Zakiyanov O, Kalousová M, Zima T, Tesař V.

Kidney Blood Press Res. 2019;44(3):298-330. doi: 10.1159/000499876. Epub 2019 Jun 11. Review.

4.

Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: a prospective observational cohort study.

Kalousová M, Dusilová-Sulková S, Kuběna AA, Zakiyanov O, Tesař V, Zima T.

Physiol Res. 2019 Jun 6. [Epub ahead of print]

5.

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT.

Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29.

PMID:
30926722
6.

Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.

Maixnerova D, Ling C, Hall S, Reily C, Brown R, Neprasova M, Suchanek M, Honsova E, Zima T, Novak J, Tesar V.

PLoS One. 2019 Feb 22;14(2):e0212254. doi: 10.1371/journal.pone.0212254. eCollection 2019. Erratum in: PLoS One. 2019 Jul 12;14(7):e0219947.

7.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Mar;78(3):399-405. doi: 10.1136/annrheumdis-2018-214245. Epub 2019 Jan 5.

PMID:
30612116
8.

Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis.

Menez S, Hruskova Z, Scott J, Cormican S, Chen M, Salama AD, Alasfar S, Little MA, Safrankova H, Honsova E, Tesar V, Geetha D.

Am J Nephrol. 2018;48(6):465-471. doi: 10.1159/000494840. Epub 2018 Nov 23.

PMID:
30472700
9.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
10.

Assessment of renal function before contrast media injection: right decisions based on inaccurate estimates.

Ptáčník V, Zogala D, Skibová D, Jiskrová H, Trnka J, Tesař V, Ryšavá R, Šámal M.

Eur Radiol. 2019 Jun;29(6):3192-3199. doi: 10.1007/s00330-018-5753-z. Epub 2018 Nov 9.

PMID:
30413953
11.

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.

Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, Lieberman K, Marder B, Meyers KE, Mustafa E, Radhakrishnan J, Srivastava T, Stepanians M, Tesar V, Zhdanova O, Komers R; DUET Study Group.

J Am Soc Nephrol. 2018 Nov;29(11):2745-2754. doi: 10.1681/ASN.2018010091.

PMID:
30361325
12.

Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes.

Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Solomons N, Houssiau FA, Romero-Diaz J, Mejia-Vilet J, Rovin BH.

Arthritis Rheumatol. 2019 Mar;71(3):411-419. doi: 10.1002/art.40724. Epub 2019 Feb 1.

PMID:
30225865
13.

Serum hepcidin is increased in ANCA-associated vasculitis and correlates with activity markers.

Přikryl P, Hrušková Z, Konopásek P, Hladinová Z, Tesař V, Vokurka M.

Physiol Res. 2018 Dec 18;67(6):945-954. Epub 2018 Sep 11.

14.

Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Geetha D, Jin Q, Scott J, Hruskova Z, Hanouneh M, Little MA, Tesar V, Seo P, Jayne D, Pagnoux C.

Kidney Int Rep. 2018 May 24;3(5):1039-1049. doi: 10.1016/j.ekir.2018.05.007. eCollection 2018 Sep. Review.

15.

Mutational screening of inverted formin 2 in adult-onset focal segmental glomerulosclerosis or minimal change patients from the Czech Republic.

Safarikova M, Stekrova J, Honsova E, Horinova V, Tesar V, Reiterova J.

BMC Med Genet. 2018 Aug 20;19(1):147. doi: 10.1186/s12881-018-0667-9.

16.

Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.

Hruskova Z, Pippias M, Stel VS, Abad-Díez JM, Benítez Sánchez M, Caskey FJ, Collart F, De Meester J, Finne P, Heaf JG, Magaz A, Palsson R, Reisæter AV, Salama AD, Segelmark M, Traynor JP, Massy ZA, Jager KJ, Tesar V.

Am J Kidney Dis. 2019 Feb;73(2):184-193. doi: 10.1053/j.ajkd.2018.05.016. Epub 2018 Aug 16.

PMID:
30122544
17.

Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus.

Hruskova Z, Tesar V.

Expert Opin Biol Ther. 2018 Sep;18(9):989-996. doi: 10.1080/14712598.2018.1504918. Epub 2018 Jul 31. Review.

PMID:
30040494
18.

Bilineal inheritance of pathogenic PKD1 and PKD2 variants in a Czech family with autosomal dominant polycystic kidney disease - a case report.

Elisakova V, Merta M, Reiterova J, Baxova A, Kotlas J, Hirschfeldova K, Obeidova L, Tesar V, Stekrova J.

BMC Nephrol. 2018 Jul 4;19(1):163. doi: 10.1186/s12882-018-0978-2.

19.

Avacopan in the treatment of ANCA-associated vasculitis.

Tesar V, Hruskova Z.

Expert Opin Investig Drugs. 2018 May;27(5):491-496. doi: 10.1080/13543784.2018.1472234. Epub 2018 May 8. Review.

PMID:
29718732
20.

Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):301-308. doi: 10.1093/ndt/gfy106.

21.

Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy.

Coppo R, Peruzzi L, Loiacono E, Bergallo M, Krutova A, Russo ML, Cocchi E, Amore A, Lundberg S, Maixnerova D, Tesar V, Perkowska-Ptasińska A, Durlik M, Goumenos D, Gerolymos M, Galesic K, Toric L, Papagianni A, Stangou M, Mizerska-Wasia Membek M, Gesualdo L, Montemurno E, Benozzi L, Cusinato S, Hryszko T, Klinger M, Kamińska D, Krajewska M; VALIGA Study Group of the ERA-EDTA Immunonephrology Working Group.

Nephrol Dial Transplant. 2019 Apr 1;34(4):587-596. doi: 10.1093/ndt/gfy064.

PMID:
29635535
22.

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.

Čertíková Chábová V, Kujal P, Škaroupková P, Varňourková Z, Vacková Š, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, Hwang SH, Hammock BD, Imig JD, Tesař V, Červenka L.

Kidney Blood Press Res. 2018;43(2):329-349. doi: 10.1159/000487902. Epub 2018 Mar 6.

23.

Management of Elderly Patients with Rapidly Progressive Glomerulonephritis.

Hruskova Z, Tesar V.

Blood Purif. 2018;45(1-3):213-217. doi: 10.1159/000485368. Epub 2018 Jan 26.

24.

Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis.

Tycová I, Hrubá P, Maixnerová D, Girmanová E, Mrázová P, Straňavová L, Zachoval R, Merta M, Slatinská J, Kollár M, Honsová E, Tesař V, Viklický O.

Physiol Res. 2018 Mar 16;67(1):93-105. Epub 2017 Nov 10.

25.

[Gliflozins slow down the progression of diabetic kidney disease].

Tesař V, Vachek J.

Vnitr Lek. Fall 2017;63(10):723-727. Review. Czech.

PMID:
29127757
26.

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts.

Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Segelmark M, Tesar V, Westman KWA, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

RMD Open. 2017 Jun 15;3(1):e000449. doi: 10.1136/rmdopen-2017-000449. eCollection 2017.

27.

Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.

Kalousová M, Dusilová-Sulková S, Kuběna AA, Zakiyanov O, Levová K, Bocková M, Gedeonová E, Song XC, Ermini ML, Špringer T, Homola J, Tesař V, Zima T.

Kidney Blood Press Res. 2017;42(3):509-518. doi: 10.1159/000479847. Epub 2017 Aug 30.

28.

Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.

Tesar V, Ciechanowski K, Pei Y, Barash I, Shannon M, Li R, Williams JH, Levisetti M, Arkin S, Serra A.

J Am Soc Nephrol. 2017 Nov;28(11):3404-3413. doi: 10.1681/ASN.2016111232. Epub 2017 Aug 24.

29.

Immunosuppressive Treatment in C3 Glomerulopathy: Time to Reconsider Our Approach.

Tesar V, Hruskova Z.

Am J Nephrol. 2017;46(2):93-95. doi: 10.1159/000479014. Epub 2017 Jul 13. No abstract available.

30.

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD.

Kidney Int. 2017 Sep;92(3):693-702. doi: 10.1016/j.kint.2017.03.014. Epub 2017 May 12.

31.

Understanding Histolopathologic Characteristics to Predict Renal Outcomes in Lupus Nephritis.

Tesar V, Hruskova Z.

Clin J Am Soc Nephrol. 2017 May 8;12(5):711-712. doi: 10.2215/CJN.03490317. Epub 2017 May 4. No abstract available.

32.

Belimumab in the management of systemic lupus erythematosus - an update.

Tesar V, Hruskova Z.

Expert Opin Biol Ther. 2017 Jul;17(7):901-908. doi: 10.1080/14712598.2017.1324846. Epub 2017 May 16. Review.

PMID:
28460578
33.

Proteomic approach for identification of IgA nephropathy-related biomarkers in urine.

Prikryl P, Vojtova L, Maixnerova D, Vokurka M, Neprasova M, Zima T, Tesar V.

Physiol Res. 2017 Sep 22;66(4):621-632. Epub 2017 Apr 12.

34.

Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group.

J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11.

35.

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.

Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators.

Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.

PMID:
28363480
36.

[Current options of treatment of hyponatremia].

Tesař V.

Vnitr Lek. 2016 Winter;62 Suppl 6:97-101. Czech.

PMID:
28124939
37.

[Gitelman´s syndrome as common cause of hypokalemia and hypomagnesemia].

Ryšavá R, Reiterová J, Urbanová M, Štekrová J, Lněnička P, Tesař V.

Vnitr Lek. 2016 Winter;62 Suppl 6:78-83. Czech.

PMID:
28124936
38.

[Theralite and multiple myeloma].

Lachmanová J, Tesař V, Ryšavá R, Bartková M.

Vnitr Lek. 2016 Winter;62 Suppl 6:9-13. Czech.

PMID:
28124926
39.

Tissue ischemia worsens during hemodialysis in end-stage renal disease patients.

Malik J, Kudlicka J, Lachmanova J, Valerianova A, Rocinova K, Bartkova M, Tesar V.

J Vasc Access. 2017 Jan 18;18(1):47-51. doi: 10.5301/jva.5000630. Epub 2016 Nov 22.

PMID:
27886367
40.

NETosis provides the link between activation of neutrophils on hemodialysis membrane and comorbidities in dialyzed patients.

Korabecna M, Tesar V.

Inflamm Res. 2017 May;66(5):369-378. doi: 10.1007/s00011-016-1010-6. Epub 2016 Nov 24. Review.

41.

Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study.

Neprasova M, Maixnerova D, Novak J, Reily C, Julian BA, Boron J, Novotny P, Suchanek M, Tesar V, Kacer P.

Dis Markers. 2016;2016:3650909. Epub 2016 Oct 9.

42.

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

Alberici F, Smith RM, Fonseca M, Willcocks LC, Jones RB, Holle JU, Wieczorek S, Neumann T, Martorana D, Gregorini G, Sinico RA, Bruchfeld A, Gunnarsson I, Ohlsson S, Baslund B, Tesar V, Hruskova Z, Cid MC, Vaglio A, Lyons PA, Smith KGC, Jayne DRW.

J Allergy Clin Immunol. 2017 May;139(5):1684-1687.e10. doi: 10.1016/j.jaci.2016.08.051. Epub 2016 Oct 22. No abstract available.

PMID:
27780742
43.

Erratum to: Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.

Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, Smerud HK, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.

Pediatr Nephrol. 2017 Jan;32(1):193-194. No abstract available.

44.

Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.

Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.

Pediatr Nephrol. 2017 Jan;32(1):139-150. Epub 2016 Aug 25. Erratum in: Pediatr Nephrol. 2017 Jan;32(1):193-194.

45.

Lupus Nephritis: A Different Disease in European Patients?

Tesar V, Hruskova Z.

Kidney Dis (Basel). 2015 Sep;1(2):110-8. doi: 10.1159/000438844. Epub 2015 Aug 28. Review.

46.

Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study.

Frausová D, Hrušková Z, Lánská V, Lachmanová J, Tesař V.

Arthritis Res Ther. 2016 Jul 13;18:168. doi: 10.1186/s13075-016-1055-5.

47.

Urine sCD163: a window onto glomerular inflammation.

Møller HJ, Tesar V, Little MA.

Nephrol Dial Transplant. 2016 Dec;31(12):1970-1972. Epub 2016 Jun 29. No abstract available.

PMID:
27358273
48.

Left Atrial Dysfunction in End-Stage Renal Disease Patients Treated by Hemodialysis.

Malik J, Lachmanova J, Kudlicka J, Rocinova K, Valerianova A, Bartkova M, Tesar V.

Nephron. 2016;133(3):169-74. doi: 10.1159/000447500. Epub 2016 Jun 25.

PMID:
27344674
49.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23. Erratum in: Ann Rheum Dis. 2017 Aug;76(8):1480.

50.

Moderator's view: Cyclophosphamide in lupus nephritis.

Tesar V.

Nephrol Dial Transplant. 2016 Jul;31(7):1058-61. doi: 10.1093/ndt/gfw067. Epub 2016 May 14.

PMID:
27190357

Supplemental Content

Support Center